132 related articles for article (PubMed ID: 15541482)
1. Rituximab in primary conjunctiva lymphoma.
Zinzani PL; Alinari L; Stefoni V; Loffredo A; Pichierri P; Polito E
Leuk Res; 2005 Jan; 29(1):107-8. PubMed ID: 15541482
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of refractory low grade duodenal lymphoma with rituximab, an anti-CD20 monoclonal antibody.
Ahmed S; Singh A; Krauss J; Wentz T; Gunaratnam NT
Am J Clin Oncol; 2003 Aug; 26(4):408-10. PubMed ID: 12902896
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva.
Nückel H; Meller D; Steuhl KP; Dührsen U
Eur J Haematol; 2004 Oct; 73(4):258-62. PubMed ID: 15347312
[TBL] [Abstract][Full Text] [Related]
4. [Rituximab in the treatment of indolent non-Hodgkin's lymphoma].
Aurer I; Mitrović Z; Radman I; Kovacević-Metelko J; Nemet D; Serventi-Seiwerth R; Stern-Padovan R; Jakic-Razumović J; Nola M; Zupancić-Salek S; Sertić D; Labar B
Lijec Vjesn; 2004; 126(11-12):307-11. PubMed ID: 16082888
[TBL] [Abstract][Full Text] [Related]
5. Intralesional rituximab: a new therapeutic approach for patients with conjunctival lymphomas.
Ferreri AJ; Govi S; Colucci A; Crocchiolo R; Modorati G
Ophthalmology; 2011 Jan; 118(1):24-8. PubMed ID: 20709407
[TBL] [Abstract][Full Text] [Related]
6. Intrapleural instillation of rituximab for the treatment of malignant pleural effusions in NHL.
Schmidt HH; Renner H; Linkesch W
Haematologica; 2004 Nov; 89(11):ECR39. PubMed ID: 15533844
[TBL] [Abstract][Full Text] [Related]
7. Rituximab (anti-CD20 monoclonal antibody) in lymphoproliferative malignancies: Tata Memorial experience.
Biswas G; Parikh PM; Nair R; Bhagwat R; Bakshi A; Prabhash K; Vora A; Gupta S; Pai VR; Menon H; Sastry PS
J Assoc Physicians India; 2006 Jan; 54():29-33. PubMed ID: 16649735
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
9. Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma.
Gajra A; Vajpayee N; Grethlein SJ
Am J Hematol; 2004 Oct; 77(2):196-7. PubMed ID: 15389902
[TBL] [Abstract][Full Text] [Related]
10. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy.
Rawal YB; Nuovo GJ; Frambach GE; Porcu P; Baiocchi RA; Magro CM
J Cutan Pathol; 2005 Oct; 32(9):616-21. PubMed ID: 16176299
[TBL] [Abstract][Full Text] [Related]
11. Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody.
Lacouture ME; Baron JM; Jani AB; Laumann AE; Soltani K
Clin Exp Dermatol; 2005 Jan; 30(1):46-8. PubMed ID: 15663503
[TBL] [Abstract][Full Text] [Related]
12. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
Collins-Burow B; Santos ES
Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
[TBL] [Abstract][Full Text] [Related]
13. Rituximab immunotherapy for ocular adnexal lymphoma: clinicopathologic correlation with 5-year follow-up.
Sokol JA; Landau L; Lauer SA
Ophthalmic Plast Reconstr Surg; 2009; 25(4):322-4. PubMed ID: 19617799
[TBL] [Abstract][Full Text] [Related]
14. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
15. Primary non-Hodgkin's lymphoma in the esophagus.
Zhu Q; Xu B; Xu K; Li J; Jin XL
J Dig Dis; 2008 Nov; 9(4):241-4. PubMed ID: 18959598
[TBL] [Abstract][Full Text] [Related]
16. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma.
Roguedas AM; Watier H; Paintaud G; de Muret A; Vaillant L; Machet L
Br J Dermatol; 2005 Mar; 152(3):541-4. PubMed ID: 15787825
[TBL] [Abstract][Full Text] [Related]
17. Intraocular use of rituximab.
Kitzmann AS; Pulido JS; Mohney BG; Baratz KH; Grube T; Marler RJ; Donaldson MJ; O'Neill BP; Johnston PB; Johnson KM; Dixon LE; Salomao DR; Cameron JD
Eye (Lond); 2007 Dec; 21(12):1524-7. PubMed ID: 17464308
[TBL] [Abstract][Full Text] [Related]
18. Targeted monoclonal antibody therapy and radioimmunotherapy for lymphoproliferative disorders of the ocular adnexa.
Shome D; Esmaeli B
Curr Opin Ophthalmol; 2008 Sep; 19(5):414-21. PubMed ID: 18772675
[TBL] [Abstract][Full Text] [Related]
19. FcgammaRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients.
Paiva M; Marques H; Martins A; Ferreira P; Catarino R; Medeiros R
Cancer Genet Cytogenet; 2008 May; 183(1):35-40. PubMed ID: 18474295
[TBL] [Abstract][Full Text] [Related]
20. CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma.
van Meerten T; Hagenbeek A
Neth J Med; 2009; 67(7):251-9. PubMed ID: 19687518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]